Jonathan P Butchar PhD

Jonathan P Butchar PhD
Res Asst ProfessorCollege of Medicinebutchar.2@osu.edu
415 Davis Heart & Lung Research Inst 473 W 12th Avenue Columbus Ohio 43210
Phone:614-247-6788Fax: 614-247-4575
  • Innate Immunity

General Research Interest

Monocyte / macrophage immune responses within the context of antibody therapy.

Research Description

Monocytes / macrophages can engulf or even directly kill antibody-coated tumor cells, and this is mediated largely through Fc-gamma receptors. These cells can also respond to pathogens such as bacteria or viruses by activation of Toll-like receptors. Such Toll-like receptor activation has been shown to enhance Fc-gamma receptor function. My work involves bringing pathogenesis and tumor immunotherapy together by studying the interactions between Fc-gamma receptor and Toll-like receptor signaling. The ultimate goal is to help improve the efficacy of antibody therapy.

Transinstitutional Work

As the focus of my work is on antibody therapy, I actively collaborate with Dr. John Byrd and Dr. William Carson at the OSU CCC. For basic research on Toll-like receptor signaling I have been collaborating with Dr. Amal Amer at the OSU CMIB and with Dr. Thirumala-Devi Kanneganti of St. Jude Children’s Research Hospital (Memphis, TN).

Current Publications

  • Byrd JCOcaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.MAbs 6 748-54 5/1/2014
  • Parsa KVA novel immunomodulatory function of PHLPP1: inhibition of iNOS via attenuation of STAT1 ser727 phosphorylation in mouse macrophages.J Leukoc Biol 1/17/2014
  • Butchar JPMonocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets?Front Cell Infect Microbiol 4 18 1/1/2014
  • Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani SFcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.J Biol Chem 288(37) 26800-9 9/13/2013
  • Jones J, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, , McGourty J, Moledor M, Lowe R, Setter B, , Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy NGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs 5(5) 723-35 9/1/2013
  • Shah P, Fatehchand K, Patel H, Fang H, Justiniano SE, Mo X, Jarjoura D, Tridandapani S, Butchar JPToll-like receptor 2 ligands regulate monocyte Fcγ receptor expression and function.J Biol Chem 288(17) 12345-52 4/26/2013
  • Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JCComparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.J Immunol 190(6) 2702-11 3/15/2013
  • Simcox ANew negative feedback regulators of Egfr signaling in Drosophila.Genetics 191(4) 8/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu